Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Asia Trial Setbacks, Asset Returns Symptomatic Of Industry Challenges?

While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.

Asia Pacific Commercial Deals

A Wild CAR-T Race In China: The Hype, Reality And What Works

As China overtakes the US as the largest developer of cell therapies including CAR-Ts, multiple issues ranging from clinical data to manufacturing are surfacing, potentially derailing a promising field. Executives from leading players Fosun-Kite, Juno-Wuxi and local heavyweight Legend shared insights on what works and what's needed to get things rights at a recent meeting in Suzhou.

China Clinical Trials Research & Development